Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study

被引：53

作者：

Nigro, Olga ^{[1
]}

Pinotti, Graziella ^{[1
]}

De Galitiis, Federica ^{[2
]}

Di Pietro, Francesca Romana ^{[2
,3
]}

Giusti, Raffaele ^{[3
]}

Filetti, Marco ^{[3
]}

Bersanelli, Melissa ^{[4
]}

Lazzarin, Alessandro ^{[4
]}

Bordi, Paola ^{[4
]}

Catino, Annamaria ^{[5
]}

Pizzutilo, Pamela ^{[5
]}

Galetta, Domenico ^{[5
]}

Marchetti, Paolo ^{[2
,6
]}

Botticelli, Andrea ^{[6
]}

Scagnoli, Simone ^{[6
]}

Russano, Marco ^{[7
]}

Santini, Daniele ^{[7
]}

Torniai, Mariangela ^{[8
]}

Berardi, Rossana ^{[8
]}

Ricciuti, Biagio ^{[9
]}

De Giglio, Andrea ^{[9
]}

Chiari, Rita ^{[10
]}

Russo, Alessandro ^{[11
]}

Adamo, Vincenzo ^{[11
]}

Tudini, Marianna ^{[12
]}

Silva, Rosa Rita ^{[12
]}

Bolzacchini, Elena ^{[13
]}

Giordano, Monica ^{[13
]}

Di Marino, Pietro ^{[14
]}

De Tursi, Michele ^{[15
]}

Rijavec, Erika ^{[16
]}

Ghidini, Michele ^{[16
]}

Vallini, Ilaria ^{[1
]}

Stucci, Luigia Stefania ^{[17
]}

Tucci, Marco ^{[17
,25
]}

Pala, Laura ^{[18
]}

Conforti, Fabio ^{[18
]}

Queirolo, Paola ^{[18
]}

Tanda, Enrica ^{[19
]}

Spagnolo, Francesco ^{[19
]}

Cecchi, Federica ^{[19
]}

Bracarda, Sergio ^{[20
]}

Macrini, Serena ^{[20
]}

Santoni, Matteo ^{[21
]}

Battelli, Nicola ^{[21
]}

Fargnoli, Maria Concetta ^{[22
,23
]}

Porzio, Giampiero ^{[22
,24
]}

Tuzi, Alessandro ^{[1
]}

Suter, Matteo Basilio ^{[1
]}

Ficorella, Corrado ^{[22
,24
]}

机构：

[1] Osped Circolo & Fdn Macchi, ASST Sette Laghi, Med Oncol, Varese, Italy

[2] IDI IRCCS, Oncol & Oncol Dermatol, Rome, Italy

[3] Azienda Osped Univ St Andrea, Med Oncol, Rome, Italy

[4] Azienda Osped Univ Parma, Med Oncol, Parma, Italy

[5] IRCCS Ist Tumori Giovanni Paolo II, Thorac Oncol Unit, Bari, Italy

[6] Univ Roma La Sapienza, Dipartimento Sci Med Chirurg & Med Traslaz, Rome, Italy

[7] Med Oncol, Campus Biomed, Rome, Italy

[8] Univ Politecn Marche, Clin Oncol, Azienda Osped Univ Osped Riuniti Umberto 1, GM Lancisi, Ancona, Italy

[9] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy

[10] Osped Riuniti Padova Sud Madre Teresa Di Calcutta, Med Oncol, Monselice, Italy

[11] Univ Messina, AO Papardo & Dept Human Pathol, Med Oncol, Messina, Italy

[12] ASUR Marche, Area Vasta 2, Med Oncol, Fabriano, Italy

[13] Osped St Anna, ASST Lariana, Med Oncol, Como, Italy

[14] SS Annunziata Hosp, Clin Oncol Unit, Chieti, Italy

[15] Univ G DAnnunzio, Dept Med Oral & Biotechnol Sci, Chieti, Italy

[16] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Med Oncol Unit, Milan, Italy

[17] Univ Bari, Med Oncol Unit, Dept Biomed Sci & Human Oncol, Bari, Italy

[18] IRCCS, European Inst Oncol, Div Med Oncol Melanoma Sarcoma & Rare Tumors, IEO, Milan, Italy

[19] Osped Policlin San Martino, IRCCS, Genoa, Italy

[20] Santa Maria Hosp, Dept Med Oncol, Terni, Italy

[21] Macerata Hosp, Dept Oncol, Macerata, Italy

[22] St Salvatore Hosp, Dept Dermatol, Laquila, Italy

[23] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[24] St Salvatore Hosp, Med Oncol, Laquila, Italy

[25] Tumori Inst Giovanni Paolo II, Natl Canc Res Ctr, Bari, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2020年 / 134卷

关键词：

Immunotherapy; Immune checkpoint; Nivolumab; Pembrolizumab; Atezolizumab; Immune-related adverse events; ELDERLY-PATIENTS; CANCER;

D O I：

10.1016/j.ejca.2020.04.025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Data on spectrum and grade of immune-related adverse events (irAEs) in long-term responders to immune checkpoint inhibitors (ICIs) are lacking. Methods: We performed a retrospective multicenter study to characterized irAEs occurring after a 12-months minimum treatment period with PD-(L)1 ICIs in patients with advanced cancer. IrAEs were categorized into 'early' (<= 12 months) and 'late' (>12 months). Results: From September 2013 to October 2019, 436 consecutive patients were evaluated. Two hundred twenty-three experienced any grade early-irAEs (51.1%), whereas 132 experienced any grade late-irAEs (30.3%) (p < 0.0001). Among the latter, 29 (22%) experienced a recurrence of an early-irAEs, whereas 103 (78%) experienced de novo late-irAEs involving different system/organ. Among patients with late-irAEs, 21 experienced GIII/GIV irAEs (4.8%). Median time to onset of early-irAEs was 3.4 months (95% confidence interval [CI]: 2.8-4.2), whereas the median time to onset of late-irAEs was 16.6 months (95% CI: 15.8-17.6). Cumulative time-adjusted risk of disease progression according to both the early-irAEs (hazard ratio [HR] = 0.63 [95% CI: 0.30-1.29], p = 0.204) and late-irAEs occurrence revealed no statistically significant differences (HR = 0.75 [95% CI: 0.37-1.56], p = 0.452). In addition, the time-adjusted cumulative risk of death in accordance with both early-irAEs (HR = 0.79 [95% CI: 0.34-1.86], p = 0.598) and late-irAEs (HR = 0.92 [95% CI: 0.49-1.74], p = 0.811) did not show statistically significant differences. Conclusion: Although less frequent than early-irAEs, late-irAEs are quite common in long responders to PD-(L)1 ICIs and are different in terms of spectrum and grade. Time-adjusted analysis revealed that the cumulative risk of disease progression and death were not significantly reduced in patients who experienced late-irAEs. (C) 2020 Elsevier Ltd. All rights reserved.

引用

页码：19 / 28

页数：10

共 50 条

[21] Management of Immune-Related Cutaneous Adverse Reactions to PD-1 and PD-L1 Inhibitors for the Inpatient Dermatologist
Chadha, Simran
Para, Andrew J.
Choi, Jennifer
CURRENT DERMATOLOGY REPORTS, 2020, 9 (04) : 231 - 243
[22] Management of Immune-Related Cutaneous Adverse Reactions to PD-1 and PD-L1 Inhibitors for the Inpatient Dermatologist
Simran Chadha
Andrew J. Para
Jennifer Choi
Current Dermatology Reports, 2020, 9 : 231 - 243
[23] Cardiovascular adverse events and immune-related adverse events associated with PD-1/PD-L1 inhibitors for head and neck squamous cell carcinoma (HNSCC)
Abulizi, Adila
Yan, Guangpeng
Xu, Qian
Muhetaer, Reyihanguli
Wu, Shihan
Abudukelimu, Kudelaiti
Chen, Xi
Liu, Chengjiang
Li, Jun
SCIENTIFIC REPORTS, 2024, 14 (01):
[24] Immune-related thyroid dysfunction in lung cancer patients treated with PD-1/PD-L1 checkpoint inhibitors
Bulusu, Venkata
Jessop, Susan
Paul, Sherin
Chapman, Timothy
Aslam, Shahzeena
Jeffs, Yvonne
Punnen, Geethu
Geetha, Anil
Hutka, Margaret
LUNG CANCER, 2023, 178 : S30 - S30
[25] Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition
Oppel-Heuchel, H.
Grimm, M. -O.
UROLOGE, 2016, 55 (05): : 677 - 688
[26] Immune-Related Adverse Events and their Association with Effectiveness of PD-1/PD-L1 Inhibitors in NSCLC: A Real-World Study from China
Chen, X.
Fang, J.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S303 - S303
[27] Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint
Magiera-Mularz, Katarzyna
Skalniak, Lukasz
Zak, Krzysztof M.
Musielak, Bogdan
Rudzinska-Szostak, Ewa
Berlicki, Lukasz
Kocik, Justyna
Grudnik, Przemyslaw
Sala, Dominik
Zarganes-Tzitzikas, Tryfon
Shaabani, Shabnam
Doemling, Alexander
Dubin, Grzegorz
Holak, Tad A.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (44) : 13732 - 13735
[28] Immunological features of immune-related adverse events during anti-PD-1/PD-L1 immune checkpoint inhibition
Goswami, Meghali
Gui, Gege
Lindblad, Katherine
Del Rivero, Jaydira
Marte, Jennifer
Dagur, Pradeep
Destefano, Christin
Thompson, Julie
Popescu, Bogdan
Dillon, Laura
Johnson, Cheryl
Soldin, Steven
Lai, Catherine
Gulley, James
Hourigan, Christopher
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[29] Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
Yan, Ting
Long, Minghui
Liu, Chaoyi
Zhang, Jiwen
Wei, Xingyu
Li, Fei
Liao, Dehua
FRONTIERS IN PHARMACOLOGY, 2025, 16
[30] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
Duruisseaux, Michael
Rouquette, Isabelle
Adam, Julien
Cortot, Alexis
Cazes, Aurelie
Gibault, Laure
Damotte, Diane
Lantuejoul, Sylvie
ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78

← 1 2 3 4 5 →